We Work for Health | Washington

12/23/2025

Happy Holidays from the We Work for Health Washington team!

12/19/2025

Congress is now considering legislation to bring greater transparency and accountability to PBMs.

The House PBM Reform Act (HR 4317) and the Senate PBM Price Transparency and Accountability Act would change how PBMs are allowed to operate in Medicare: https://ncpa.org/newsroom/executive-update/2025/12/12/deck-halls-hope-pbm-reform-ncpa-executive-update-december-12

12/17/2025

"The evidence remains clear: the hepatitis B birth dose is safe and an essential component in helping children develop immunity against a serious, potentially lifelong disease."

We know vaccines work: https://www.aap.org/en/news-room/news-releases/aap/2025/statement-from-leading-medical-health-and-patient-advocacy-groups-on-cdc-vaccine-meeting/

12/16/2025

The Trump Administration laid out a plan to set maximum fair prices for the IPAY 2027 selected drugs, cautioning that such price controls could harm patients and reduce innovation.

We Work For Health responded:

November 26, 2025 (Washington, DC) We Work For Health Executive Director Dan Leonard issued the following statement in response to the administration’s announcement on the Maximum Fair Prices (MFP) for IPAY 2027 selected drugs: “We Work For Health has been sounding the alarm about the dangers of...

12/12/2025

The U.S. Senate Aging Committee recently held a hearing focused on a major concern: Competition from China as a vulnerability in U.S. drug supply chain.

The We Work for Health blog covers the issue:

Members of the Senate Special Committee on Aging convened last week to hear from witnesses on restoring trust in American-made medicines. The hearing highlighted urgent concerns about America’s reliance on foreign nations, particularly China, for critical drug ingredients and finished medications....

12/10/2025

We Work for Health's recent blog post highlights a striking indicator of the momentum of China’s biopharma sector: Biotech stocks in China are up 80% versus 20% in the U.S.

Learn more:

Chinese biotech stock is reportedly “booming” while outperforming its U.S. counterpart, delivering the latest data point in a worrisome trend for America’s patients, economy, and national security. According to a recent STAT article, while U.S. biotech stock is up 20% this year, China's is up ...

12/08/2025

"This bipartisan legislation is a decisive step toward making the prescription drug market easier to navigate for both patients and pharmacies."

: Senator Mike Crapo and Senator Ron Wyden are re-introducing federal reform efforts.

Read more:

Wyden, Crapo Introduce Bipartisan Pharmacy Benefit Manager Legislation

12/05/2025

" and their affiliates decide which drugs patients can access, how cost-sharing is designed, and how much of a manufacturer’s discount actually reaches the consumer.

Spoiler: Very little does."

https://dcjournal.com/we-cant-have-lower-insurance-premiums-and-drug-costs-without-reforming-pbms/

12/03/2025

"For too long, foreign competitors such as China have had a viselike grip on the global biopharmaceutical supply chain."

https://www.washingtontimes.com/news/2025/nov/18/securing-medicine-manufacturing-key-america-first-agenda/

12/02/2025

"If policymakers are serious about reducing healthcare costs, they need to start with an honest assessment: America has a healthcare cost problem – not just a drug cost problem."

https://www.linkedin.com/pulse/its-time-honest-conversation-us-healthcare-costs-drug-dan-leonard-4ml0e/

11/28/2025

"Europe’s retreat from biomedical innovation did not occur in a vacuum, and neither would America’s. As the West throttles its science, China is racing ahead."

https://dcjournal.com/america-cant-win-by-copying-europes-failures/

11/26/2025

"Supporters bill as a way to cut costs. In reality, it would import Europe’s system of government-set prices, and with it the predictable consequences: fewer available treatments, longer waits and stalled medical innovation."

https://www.thewellnews.com/opinions/most-favored-nation-drug-pricing-fails-patients-and-their-caregivers/